February 27, 2020

Interventional Oncology Market – Global Industry Analysis, Share and Forecast to 2025

Buy Now on Acute Market Reports

As of 2019, the global interventional oncology market is expected to grow to $1,506.3 million by 2025 at a CAGR of 7.7 percent. Interventional oncology is an emerging and rapidly growing offshoot of interventional radiology that uses minimally invasive procedures for cancer patients to be diagnosed, treated and palliated. Increasing preference for minimally invasive treatment procedures, increased cancer incidence, increased hospital number, and radiology technological advances are key factors driving the adoption of interventional oncology in many countries around the globe.

Increasing cancer incidence propels the growth of the market for interventional oncology

Cancer is the world’s second-largest cause of death and in 2018 was responsible for an estimated 9.6 million deaths. In low-and-middle-income countries, about 70 percent of cancer deaths occur. Diagnosis of the late stage and inaccessible treatment are the major factors responsible for rising cancer mortality worldwide. In 2017, according to the WHO, only 26 percent of low-income countries reported having pathology services generally available in the public sector. Over 90% of high-income countries said that treatment services were available. Similarly, according to GLOBOCAN, around 14.1 million new cases of cancer were diagnosed worldwide in 2012, which increased by ~28 percent to reach 18.1 million new cases in 2018. It is further expected that these numbers will rise to 29.5 million cases by 2040.

Also, in 2017, U.S. cancer care expenditure was $147.3 billion. Costs are likely to increase in the future as the population ages and the incidence and prevalence of cancer increases. Thus, factors such as increasing cancer incidence, rising cancer-related healthcare expenses, and demand for advanced cancer care options drive the adoption of interventional oncology.

Developing economies have significant opportunities to support market growth

Health expenditure ($/capita) is steadily increasing in developing regions, according to the Organization for Economic Co-operation and Development (OECD). The increasing spending is a positive indicator for any market for medical devices, including interventional oncology. Increasing health expenditure is also an indicator of improving patient access to healthcare, which ultimately leads to improved medical facilities and associated treatment development. According to the World Health Organization (WHO), health spending is increasing on average 6 percent annually in low-and-middle-income countries compared with 4 percent in high-income countries. For the above reasons, therefore, the adoption of advanced tools and equipment, including interventional oncology procedures is increasing across Asia and Latin American regions in emerging countries.

Key findings in the Market Study for Global Interventional Oncology: 

Tumour embolization procedures to witness the greatest demand by 2025

Tumour embolization procedures commanded the largest share of the global oncology intervention market in 2018, mainly due to their extensive use with high sensitivity, specificity, and accuracy to detect and characterize tumors. Additionally, advances in embolization procedures along with research programs to improve the efficiency of yttrium 90 isotopes have resulted in an increased worldwide demand for embolization procedures.

By 2025, liver cancer will dominate the interventional oncology market

In 2018, liver cancer commanded the largest share of global interventional oncology primarily due to the availability of a wide range of embolization and ablation products globally for the treatment of liver cancer and the increasing prevalence of the disease and related mortality. Also, this segment is also estimated to grow at the highest CAGR of 8.0 percent during the forecast period with rising disease diagnosis and treatment rates, with increased awareness of the fatality and benefits of early diagnosis and treatment worldwide, and increased access to innovative products and expanded coverage of reimbursement.

In 2018, hospitals commanded the largest share of the global oncology intervention market. The growth of this market is driven by an increasing number of private hospitals in the emerging countries, coupled with the large pool of cancer patient population visiting diagnostic and treatment hospitals. For example, the total number of hospitals in China has increased significantly over the past decade, according to the Commonwealth Fund, from approximately 18,700 in 2005 to ~27,600 in 2015 and ~31,056 in 2017. In addition to the factors as mentioned above, increased reimbursement for interventional oncology procedures, improved healthcare infrastructure, and global accessibility to hospitals are the key factors further supporting the growth of the interventional oncology market in hospitals.

In 2018, North America captured the largest share of the global oncology intervention market, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. However, due to the accelerated economic growth of many countries in this region and growing government focus on the healthcare sector, Asia-Pacific will become the fastest growing regional market. Additionally, government initiatives aimed at developing health care facilities, increasing the incidence and prevalence of cancer; increasing awareness of the overall availability of health and treatment; increasing the number of middle-class people and their level of disposable income; increasing penetration of health insurance; and growing ageing in the region are key drivers of growth.

The report includes a competitive landscape based on a comprehensive evaluation of key strategic developments adopted over the past five years (2016-2019) by the industry’s leading market participants.

The key players in the global interventional oncology market research report are

  • Boston Scientific Corporation,
  • C. R. Bard, Inc.,
  • Medtronic plc,
  • Cook Medical LLC,
  • Merit Medical Systems, Inc.,
  • Profound Medical Corp,
  • AngioDynamics, Inc.,
  • BTG plc,
  • Terumo Corporation,
  • HealthTronics, Inc.,
  • EDAP TMS S.A.,
  • Neuwave Medical, Inc.,
  • Sirtex Medical Limited,
  • Trod Medical,
  • Teleflex Incorporated,
  • Sanaru.

Request Sample

Table Of Content:

1 Interventional Oncology Device Overview
1.1 Product Overview and Scope of Interventional Oncology Device
1.2 Classification of Interventional Oncology Device
1.2.1 Type I
1.2.2 Type II
1.2.3 Type III
1.3 Application of Interventional Oncology Device
1.3.1 Application 1
1.3.2 Application 2
1.3.3 Application 3
1.4  Market Size Sales (Value) and Revenue (Volume) of Interventional Oncology Device (2011-2021)
1.4.1  Interventional Oncology Device Sales and Growth Rate (2011-2021)
1.4.2  Interventional Oncology Device Revenue and Growth Rate (2011-2021)

2  Interventional Oncology Device Competition by Manufacturers
2.1  Interventional Oncology Device Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2  Interventional Oncology Device Revenue and Share by Manufactures (2015 and 2016)
2.3  Interventional Oncology Device Average Price by Manufactures (2015 and 2016)
2.4 Interventional Oncology Device Market Competitive Situation and Trends
2.4.1 Interventional Oncology Device Market Concentration Rate
2.4.2 Interventional Oncology Device Market Share of Top 3 and Top 5 Manufacturers
2.4.3 Mergers & Acquisitions, Expansion

3  Interventional Oncology Device Sales (Volume) and Revenue (Value) by Type (2011-2016)
3.1  Interventional Oncology Device Sales and Market Share by Type (2011-2016)
3.2  Interventional Oncology Device Revenue and Market Share by Type (2011-2016)
3.3  Interventional Oncology Device Price by Type (2011-2016)
3.4  Interventional Oncology Device Sales Growth Rate by Type (2011-2016)

4 Interventional Oncology Device Sales (Volume) by Application (2011-2016)
4.1 Interventional Oncology Device Sales and Market Share by Application (2011-2016)
4.2 Interventional Oncology Device Sales Growth Rate by Application (2011-2016)
4.3 Market Drivers and Opportunities

5  Interventional Oncology Device Manufacturers Profiles/Analysis
5.1 Philips Volcano
5.1.1 Company Basic Information, Manufacturing Base and Competitors
5.1.2 Interventional Oncology Device Product Type, Application and Specification
5.1.2.1 Type I
5.1.2.2 Type II
5.1.3 Philips Volcano Interventional Oncology Device Sales, Revenue, Price and Gross Margin (2011-2016)
5.1.4 Main Business/Business Overview
5.2 Boston Scientific
5.2.2 Interventional Oncology Device Product Type, Application and Specification
5.2.2.1 Type I
5.2.2.2 Type II
5.2.3 Boston Scientific Interventional Oncology Device Sales, Revenue, Price and Gross Margin (2011-2016)
5.2.4 Main Business/Business Overview
5.3 GE Healthcare
5.3.2 Interventional Oncology Device Product Type, Application and Specification
5.3.2.1 Type I
5.3.2.2 Type II
5.3.3 GE Healthcare Interventional Oncology Device Sales, Revenue, Price and Gross Margin (2011-2016)
5.3.4 Main Business/Business Overview
5.4 Silicon Valley Medical Instruments
5.4.2 Interventional Oncology Device Product Type, Application and Specification
5.4.2.1 Type I
5.4.2.2 Type II
5.4.3 Silicon Valley Medical Instruments Interventional Oncology Device Sales, Revenue, Price and Gross Margin (2011-2016)
5.4.4 Main Business/Business Overview
5.5 St. Jude Medical
5.5.2 Interventional Oncology Device Product Type, Application and Specification
5.5.2.1 Type I
5.5.2.2 Type II
5.5.3 St. Jude Medical Interventional Oncology Device Sales, Revenue, Price and Gross Margin (2011-2016)
5.5.4 Main Business/Business Overview
5.6 Medtronic
5.6.2 Interventional Oncology Device Product Type, Application and Specification
5.6.2.1 Type I
5.6.2.2 Type II
5.6.3 Medtronic Interventional Oncology Device Sales, Revenue, Price and Gross Margin (2011-2016)
5.6.4 Main Business/Business Overview
5.7 Hitachi Aloka Medical America
5.7.2 Interventional Oncology Device Product Type, Application and Specification
5.7.2.1 Type I
5.7.2.2 Type II
5.7.3 Hitachi Aloka Medical America Interventional Oncology Device Sales, Revenue, Price and Gross Margin (2011-2016)
5.7.4 Main Business/Business Overview
5.8 Infraredx
5.8.2 Interventional Oncology Device Product Type, Application and Specification
5.8.2.1 Type I
5.8.2.2 Type II
5.8.3 Infraredx Interventional Oncology Device Sales, Revenue, Price and Gross Margin (2011-2016)
5.8.4 Main Business/Business Overview

6 Interventional Oncology Device Manufacturing Cost Analysis
6.1 Interventional Oncology Device Key Raw Materials Analysis
6.1.1 Key Raw Materials
6.1.2 Price Trend of Key Raw Materials
6.1.3 Key Suppliers of Raw Materials
6.1.4 Market Concentration Rate of Raw Materials
6.2 Proportion of Manufacturing Cost Structure
6.2.1 Raw Materials
6.2.2 Labor Cost
6.2.3 Manufacturing Expenses
6.3 Manufacturing Process Analysis of Interventional Oncology Device

7 Industrial Chain, Sourcing Strategy and Downstream Buyers
7.1 Interventional Oncology Device Industrial Chain Analysis
7.2 Upstream Raw Materials Sourcing
7.3 Raw Materials Sources of Interventional Oncology Device Major Manufacturers in 2015
7.4 Downstream Buyers

8 Marketing Strategy Analysis, Distributors/Traders
8.1 Marketing Channel
8.1.1 Direct Marketing
8.1.2 Indirect Marketing
8.1.3 Marketing Channel Development Trend
8.2 Market Positioning
8.2.1 Pricing Strategy
8.2.2 Brand Strategy
8.2.3 Target Client
8.3 Distributors/Traders List

9 Market Effect Factors Analysis
9.1 Technology Progress/Risk
9.1.1 Substitutes Threat
9.1.2 Technology Progress in Related Industry
9.2 Consumer Needs/Customer Preference Change
9.3 Economic/Political Environmental Change

10  Interventional Oncology Device Market Forecast (2016-2021)
10.1  Interventional Oncology Device Sales, Revenue Forecast (2016-2021)
10.2  Interventional Oncology Device Sales Forecast by Type (2016-2021)
10.3  Interventional Oncology Device Sales Forecast by Application (2016-2021)
10.4 Interventional Oncology Device Price Forecast (2016-2021)

11 Research Findings and Conclusion

12 Appendix
Disclosure Section
Research Methodology
Data Source
Disclaimer

Request Sample

Leave a Reply

Your email address will not be published. Required fields are marked *